Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNZZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for LIGAND PHARMS BETA CVR (LGNZZ) centers on regulatory documents associated with Ligand Pharmaceuticals Incorporated, the issuer identified in related filings. Although LGNZZ itself is not detailed in the excerpted registration table, the name links it to the same company whose common stock trades under the symbol LGND on The Nasdaq Global Market.
One highlighted filing is a Form 8-K in which Ligand Pharmaceuticals Incorporated reports entry into a Third Amendment to its Credit Agreement. This document explains that the company, together with certain subsidiaries as guarantors, amended a credit facility with a group of lenders and Citibank, N.A. as administrative agent, swingline lender, and letter of credit issuer. The amendment extends the maturity date and adjusts a minimum consolidated EBITDA covenant, illustrating how the issuer’s direct financial obligations and covenants evolve over time.
On this page, users can review current reports on Form 8-K and related exhibits that describe material definitive agreements and the creation or modification of direct financial obligations. These filings provide insight into the company’s borrowing arrangements, financial maintenance requirements, and relationships with its lenders.
Stock Titan enhances access to these documents by pairing them with AI-powered summaries that explain the key points of lengthy agreements and technical disclosures. Instead of reading an entire amendment or credit agreement, users can rely on concise explanations that highlight the nature of the obligation, the roles of the parties, and the main covenant changes. Real-time updates from EDGAR help ensure that new filings, such as additional amendments or related exhibits, are incorporated as they become available.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported equity compensation activity and related tax withholding in company stock. On February 14, 2026, he acquired 6,928 and 8,810 shares of common stock at no cost through grants tied to performance stock units and restricted stock units.
On February 14–15, 2026, several transactions coded “F” show blocks of common shares, including 3,211 and 4,083 shares at $183.83 per share, being withheld by the issuer to cover tax liabilities from these equity awards, rather than open‑market sales.
Ligand Pharmaceuticals Chief Financial Officer equity transactions center on PSU and RSU settlements and related tax withholding. On February 14, Octavio Espinoza acquired 7,390 and 8,810 shares of common stock at $0 per share through grants tied to performance and restricted stock units. On February 14–15, he disposed of a total of 11,763 shares at $183.83 per share in tax-withholding dispositions, where shares were withheld by the issuer to cover tax liabilities.
Ligand Pharmaceuticals CEO Todd C. Davis reported equity compensation activity involving common stock. On
Ligand Pharmaceuticals director John W. Kozarich sold 467 shares of common stock in a planned transaction. The sales occurred on February 2, 2026 at prices ranging from $191.00 to $197.195 per share in several small trades.
After these sales, Kozarich directly beneficially owned 43,187 shares of Ligand common stock. The filing notes that the transactions were executed under a written trading plan adopted on March 7, 2025 in accordance with Rule 10b5-1, which allows pre-arranged trading by insiders.
Ligand Pharmaceuticals insider selling notice: A Form 144 reports a planned sale of 467 shares of Ligand common stock through UBS Financial Services Inc., with an aggregate market value of
The shares to be sold are common stock acquired on
Form 144 notice for proposed sale of 10,000 common shares by an insider through Morgan Stanley Smith Barney LLC. The filing states the aggregate market value of the shares to be sold is $1,708,087.44 based on 10,000 shares, with approximately 19,596,560 shares outstanding for the issuer. The approximate date of sale is listed as 09/23/2025. The filer reports no securities sold in the past three months. Acquisition details show the 10,000 shares were acquired in multiple lots between 06/04/2022 and 06/06/2025 via restricted stock grants and exercised share transactions, with specific lot sizes and payment methods noted where applicable.
Form 144 notice for Ligand Pharmaceuticals, Inc. (LGNZZ): An insider filed to sell 10,000 shares of the company's common stock through Charles Schwab & Co., with an approximate aggregate market value of $1,685,000. The filing reports the shares were acquired in the open market on October 9, 2014 (payment dated October 1, 2014) and the proposed sale date is September 17, 2025 on NASDAQ. The filing states there were 19,596,560 shares outstanding, and no securities were sold by the filer in the past three months. The filer certifies no undisclosed material information is known.
Ligand Pharmaceuticals Incorporated reported that it entered into a Third Amendment to its existing credit agreement with Citibank and other lenders. The amendment extends the loan’s maturity date to September 12, 2028, giving the company more time before the debt comes due.
The amendment also tightens a key financial test. Ligand must maintain at least $55 million of consolidated EBITDA for the trailing four-quarter period ending September 30, 2025 and for each trailing four-quarter period after that. This sets a clear performance threshold the company needs to meet to stay in compliance with its credit facility.